• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease.
【24h】

The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease.

机译：黑色素瘤治疗的免疫学时代：晚期疾病中基于热休克蛋白的疫苗面临的新挑战。

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Tumor-derived heat shock protein (HSP)-peptide complexes (HSPPCs) induced immunity against malignancies in preclinical trials, working across tumor types and bypassing the need to identify single immunogenic peptides. These results paved the way for the use of human gp96 obtained from autologous tumor samples as an anti-cancer vaccine. AREAS COVERED: Autologous tumor-derived HSP gp96 peptide complex (HSPPC-96) vaccine is emerging as a tumor- and patient-specific cancer vaccine, with confirmed activity in several malignancies. It has been tested in Phase III clinical trials in advanced melanoma and kidney cancer with evidence for efficacy in patients with earlier stage disease. HSPPC-96-based vaccine demonstrated an excellent safety profile, thus emerging as a novel therapeutic approach with a suggestive role in cancer therapy. This review summarizes work on the use of HSPPC-96 as an autologous anti-tumor vaccine in advanced melanoma. Data were retrieved by PubMed and Medline research and using the authors' personal experience. EXPERT OPINION: Further investigations are needed to understand the biological basis of immune functions in order to improve the clinical outcome of HSP-based cancer therapy. In the near future, the combination of HSP-based vaccines with other biological compounds might represent a successful strategy in the therapy of advanced melanoma.
机译：引言：在临床前试验中，肿瘤衍生的热休克蛋白（HSP）-肽复合物（HSPPC）诱导了针对恶性肿瘤的免疫力，适用于各种肿瘤类型，并且无需鉴定单一的免疫原性肽。这些结果为将从自体肿瘤样品获得的人gp96用作抗癌疫苗铺平了道路。覆盖的区域：自体肿瘤来源的HSP gp96肽复合物（HSPPC-96）疫苗正在作为一种针对肿瘤和患者的癌症疫苗出现，并在多种恶性肿瘤中具有确定的活性。它已在晚期黑色素瘤和肾癌的III期临床试验中进行了测试，具有对早期疾病患者有效的证据。基于HSPPC-96的疫苗显示出出色的安全性，因此成为一种新型治疗方法，在癌症治疗中具有暗示作用。这篇综述总结了在晚期黑素瘤中使用HSPPC-96作为自体抗肿瘤疫苗的工作。数据是通过PubMed和Medline的研究并利用作者的个人经验来检索的。专家意见：为了改善基于HSP的癌症治疗的临床结果，需要进一步研究以了解免疫功能的生物学基础。在不久的将来，基于HSP的疫苗与其他生物化合物的结合可能代表着治疗晚期黑素瘤的成功策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号